GlassScriptPhysician profile
Sushee C Gadde
NPI 1043506272
$5,113.93
in general payments reported to CMS, 2019-2025
30 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $362 · 2021: $506 · 2022: $560 · 2023: $1,069 · 2024: $840 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.34 |
| Education | $109.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $674.13 | 2019-2023 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $636.19 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $573.75 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.82 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $457.37 | 2023-2025 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $435.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $252.59 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $223.20 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $187.54 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $180.32 | 2019-2025 | Farxiga |
| Edwards Lifesciences Corporation | $105.22 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $103.07 | 2025 | |
| Abbott Laboratories | $100.68 | 2020-2024 | Cardiomems, Mitraclip |
| Kiniksa Pharmaceuticals International, Plc | $92.90 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $88.28 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $78.85 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $72.83 | 2023-2024 | Inpefa |
| Cvrx, INC. | $64.53 | 2020-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $40.62 | 2023 | Arcalyst |
| United Therapeutics Corporation | $31.74 | 2024 | Tyvaso |
| Solventum Corporation | $30.36 | 2025 | Prevena |
| Boston Scientific Corporation | $25.73 | 2019-2020 | |
| Nuwellis, INC. | $25.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.41 | 2019 | |
| Inari Medical, INC. | $21.94 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Inspire Medical Systems, INC. | $21.34 | 2025 | Inspire |
| Kls-Martin L.P. | $19.67 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $17.06 | 2019 | |
| Heartflow, INC. | $15.65 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushee Gadde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.